

The impact of novel Alzheimer's Disease therapeutics on the activation of the pro-inflammatory transcription factor NF-kB

Abstract

Inflammation is a natural and beneficial response to injury and pathogen invasion. However, chronic inflammation is linked to the progression of various neurodegenerative diseases. Although the exact etiology is unknown, Alzheimer's disease is associated with the overactivation of the NF-kB inflammatory pathway. NF-kB is a transcription factor that, in an unstimulated cell, is sequestered in the cytoplasm as a complex with its inhibitor, $I\kappa B\alpha$. When the pathway is activated by an external signal, IkBa is phosphorylated and subsequently degraded in the proteasome. Liberated NF-kB translocates to the nucleus, where it acts as a transcription factor for pro-inflammatory genes, highlighting its potential as a therapeutic target. Our research investigates the exact point of interference of novel anti-inflammatory drugs (provided by P2D Biosciences) with the NF-kB pathway through Western blotting and immunofluorescence.





Figure 1. The canonical and non-canonical NF-κB signaling pathway.



- blotting
- microscopy

Lal Durmaz & Giridhar Akkaraju Department of Biology, Texas Christian University

Immunofluorescence and confocal



Funding

We would like to gratefully acknowledge funding from CSE SERC.